| Literature DB >> 18335060 |
Marta Luisa Ciofi degli Atti1, Stefano Merler, Caterina Rizzo, Marco Ajelli, Marco Massari, Piero Manfredi, Cesare Furlanello, Gianpaolo Scalia Tomba, Mimmo Iannelli.
Abstract
BACKGROUND: Individual-based models can provide the most reliable estimates of the spread of infectious diseases. In the present study, we evaluated the diffusion of pandemic influenza in Italy and the impact of various control measures, coupling a global SEIR model for importation of cases with an individual based model (IBM) describing the Italian epidemic. METHODOLOGY/PRINCIPALEntities:
Mesh:
Year: 2008 PMID: 18335060 PMCID: PMC2258437 DOI: 10.1371/journal.pone.0001790
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
School/workplace attendance and contact patterns
| School category | Age group in years | % attending population | Average number of close contacts | % of clinical cases staying at home |
| Day care | 0–2 | 14 | 20 | 90 |
| Nursery school/Kindergarten | 3–5 | 90 | 40 | 90 |
| Primary school | 6–10 | 97 | 19 | 80 |
| Middle school | 11–13 | 96 | 21 | 80 |
| High school | 14–18 | 82 | 21 | 75 |
| University | 19–24 | 31 | 34 | 50 |
| Workplace | ≥15 | 43 | 5 | 50 |
Figure 1Baseline simulations under different R0 scenarios (blue line: R0 = 2; red line: R0 = 1.7; green line: R0 = 1.4).
Bullet points represent the first Italian case and the time elapsed from the first world case.
Figure 2Spatial spread of pandemic influenza in Italy, R0 = 1.7.
Red areas represent municipalities where at least one case is present.
Clinical attack rates and peak day, by scenario and control measure.
| Control measure | Scenario | |||||||||||
| Mild | Moderate | Severe | ||||||||||
| Cumulative AR [%] (95% CI) | Peak day (95% CI) | Peak daily AR [%] (95% CI) | Million courses | Cumulative AR [%] (95% CI) | Peak day (95% CI) | Peak daily AR [%] (95% CI) | Million courses | Cumulative AR [%] (95% CI) | Peak day (95% CI) | Peak daily AR [%] (95% CI) | Million courses | |
|
| 21.2 (21.13–21.27) | 202 (200–204) | 0.42 (0.41–0.43) | - | 30.81 (30.73–30.90) | 125 (123–126) | 1.03 (1.02–1.05) | - | 38.69 (38.60–38.77) | 91 (89–92) | 1.93 (1.87–1.97) | - |
|
| ||||||||||||
|
| 21.16 (21.08–21.24) | 225 (223–228) | 0.42 (0.42–0.43) | - | 30.81 (30.74–30.88) | 135 (133–138) | 1.01 (0.99–1.03) | - | 38.72 (38.62–38.80) | 97 (95–100) | 1.90 (1.86–1.93) | - |
|
| 21.14 (21.05–21.23) | 241 (233–245) | 0.40 (0.38–0.41) | - | 30.82 (30.75–30.88) | 150 (146–152) | 1.03 (0.97–1.10) | - | 38.72 (38.62–38.81) | 108 (106–109) | 1.91 (1.84–1.94) | - |
|
| ||||||||||||
|
| 21.18 (21.06–21.26) | 207 (205–211) | 0.43 (0.43–0.43) | - | 30.81 (30.70–30.88) | 132 (130–135) | 1.03 (1.02–1.04) | - | 38.68 (38.60–38.75) | 99 (97–102) | 1.91 (1.89–1.94) | - |
|
| ||||||||||||
|
| 4.58 (4.46–4.69) | 255 (251–263) | 0.03 (0.03–0.03) | 7,3 | 15.47 (15.39–15.55) | 150 (149–151) | 0.27 (0.27–0.28) | 23,5 | 24.91 (24.83–24.98) | 104 (100–106) | 0.76 (0.75–0.77) | 35,4 |
|
| ||||||||||||
|
| 7.44 (7.36–7.54) | 238 (235–239) | 0.07 (0.07–0.07) | 14,4 | 17.81 (17.72–17.92) | 144 (141–146) | 0.36 (0.36–0.37) | 14,4 | 27.12 (27.06–27.20) | 99 (97–100) | 0.94 (0.94–0.96) | 14,4 |
|
| 7.47 (7.40–7.57) | 237 (234–241) | 0.07 (0.07–0.07) | 14,4 | 18.07 (17.97–18.14) | 133 (132–134) | 0.36 (0.36–0.37) | 14,4 | 36.29 (36.10–36.52) | 92 (89–93) | 1.91 (1.90–1.94) | 14,4 |
|
| 7.48 (7.39–7.61) | 235 (233–238) | 0.07 (0.07–0.07) | 14,4 | 25.48 (24.84–25.94) | 125 (122–126) | 1.0 (0.98–1.01) | 14,4 | 38.67 (38.58–38.75) | 92 (89–93) | 1.91 (1.90–1.94) | 14,4 |
|
| 7.66 (7.60–7.74) | 218 (211–222) | 0.08 (0.08–0.08) | 14,4 | 30.58 (30.53–30.69) | 125 (124–127) | 1.0 (0.98–1.01) | 14,4 | 38.68 (38.58–38.76) | 92 (89–93) | 1.91 (1.90–1.94) | 14,4 |
|
| 10.46 (9.9–11.19) | 182 (178–186) | 0.24 (0.20–0.28) | 14,4 | 30.80 (30.70–30.89) | 125 (124–127) | 1.0 (0.98–1.01) | 14,4 | 38.68 (38.60–38.77) | 92 (89–93) | 1.91 (1.90–1.94) | 14,4 |
|
| 17.51 (16.87–18.29) | 202 (200–203) | 0.43 (0.43–0.44) | 14,4 | 30.81 (30.72–30.89) | 125 (124–127) | 1.0 (0.98–1.01) | 14,4 | 38.68 (38.59–38.78) | 92 (89–93) | 1.91 (1.90–1.94) | 14,4 |
VE = 70%; vaccination target categories: personnel providing essential services, elderly persons, individuals 2–18 years of age
Interval (in days) from the first world case to the importation of the first case in Italy, by scenario and level of international air travel restriction.
| Time elapsed from first world case to importation in Italy (in days) (95% CI) | |||
| Scenario | |||
|
| Mild | Moderate | Severe |
| None | 77 (55,92) | 48 (34,57) | 37 (25,42) |
| 90% | 94 (72,108) | 59 (44,69) | 44 (34,51) |
| 99% | 114 (92,127) | 71 (55,79) | 53 (42,60) |
Figure 3Clinical AR, by control measure and scenario (Panel A: R0 = 1.7; Panel B: R0 = 2).
black = baseline results; light blue = 90% air travel restriction; violet = AVP to household contacts; blue = vaccination, administering first dose within 3 months of the first world case for R0 = 1.7, or within 2 months for R0 = 2; grey = 90% air travel restriction+vaccination, as reported for the blue line; green = all control measures combined; red = all control measures combined, extending AVP to school/work close contacts.
Clinical attack rates and peak day, combining vaccination with international air travel restriction, by scenario.
| Control measure | Scenario | ||||||||
| Mild | Moderate | Severe | |||||||
| Cumulative AR [%] (95% CI) | Peak day (95% CI) | Peak daily AR [%] (95% CI) | Cumulative AR [%] (95% CI) | Peak day (95% CI) | Peak daily AR [%] (95% CI) | Cumulative AR [%] (95% CI) | Peak day (95% CI) | Peak daily AR [%] (95% CI) | |
|
| |||||||||
| 1 month | 7.3 (7.2–7.4) | 277 (276–279) | 0.07 (0.07–0.07) | 17.8 (17.7–17.9) | 162 (160–163) | 0.37 (0.36–0.38) | 27.1 (27.0–27.2) | 106 (102–107) | 0.96 (0.93–0.98) |
| 2 months | 7.3 (7.3–7.4) | 277 (275–279) | 0.07 (0.07–0.07) | 17.8 (17.7–17.9) | 155 (151–157) | 0.38 (0.37–0.38) | 34.1 (33.4–34.6) | 97 (96–99) | 1.91 (1.82–1.98) |
| 3 months | 7.4 (7.3–7.5) | 275 (273–276) | 0.07 (0.07–0.07) | 20.2 (19.8–20.6) | 129 (126,130) | 0.54 (0.48–0.62) | 38.7 (38.6–38.7) | 98 (95–99) | 1.93 (1.86–1.98) |
| 4 months | 7.3 (7.3–7.5) | 265 (261–267) | 0.07 (0.07–0.08) | 29.6 (29.4–29.9) | 139 (137–140) | 1.04 (1.03–1.07) | 38.7 (38.6–38.8) | 98 (96–99) | 1.93 (1.86–1.98) |
|
| |||||||||
| 1 month | 7.3 (7.2–7.4) | 316 (311–324) | 0.07 (0.07–0.07) | 17.8 (17.7–17.9) | 179 (177–180) | 0.37 (0.36–0.37) | 27.0 (27.0–27.1) | 119 (118–121) | 0.89 (0.79–0.95) |
| 2 months | 7.3 (7.3–7.4) | 320 (313–324) | 0.07 (0.07–0.07) | 17.8 (17.7–17.9) | 171 (167–175) | 0.37 (0.35–0.38) | 29.1 (28.6–29.4) | 104 (101–109) | 1.04 (0.99–1.11) |
| 3 months | 7.3 (7.2–7.4) | 309 (302–315) | 0.07 (0.07–0.08) | 18.2 (18.1–18.4) | 156 (152–161) | 0.37 (0.36–0.38) | 38.4 (38.3–38.5) | 108 (105–109) | 1.81 (1.59–1.94) |
| 4 months | 7.3 (7.2–7.4) | 298 (291–305) | 0.07 (0.06–0.07) | 26.5 (25.9–26.8) | 150 (148–153) | 1.00 (0.95–1.03) | 38.7 (38.6–38.8) | 108 (104–109) | 1.81 (1.59–1.94) |
VE = 70%; vaccination target categories: personnel providing essential services, elderly persons, individuals 2–18 years of age
Clinical Attack rates and peak day, by combination of control measures.
| Control measure | Cumulative AR [%] (95% CI) | Peak day (95% CI) | Peak daily AR [%] (95% CI) | Millions of AVP courses used | Millions of vaccine courses used |
|
| |||||
| AVP | 4.5 (4.4–4.5) | 213 (209–215) | 0.04 (0.04–0.04) | 6.8 | 14.4 |
| AVP | 4.6 (4.6–4.7) | 186 (177–197) | 0.04 (0.04–0.04) | 7.1 | 14.4 |
| AVP | 6.7 (6.2–7.2) | 154 (150–156) | 0.15 (0.12–0.18) | 10.0 | 14.4 |
| AVP | 5.7 (5.6–5.7) | 214 (206–219) | 0.05 (0.05–0.06) | 8.7 | 14.4 |
| AVP | 5.8 (5.7–5.9) | 194 (189–197) | 0.06 (0.06–0.06) | 8.9 | 14.4 |
| AVP | 7.4 (7.2–7.8) | 155 (151–156) | 0.14 (0.12–0.16) | 11.3 | 14.4 |
| AVP | 7.1 (7.0–7.1) | 211 (207–217) | 0.07 (0.07–0.07) | 10.8 | 14.4 |
| AVP | 7.2 (7.1–7.3) | 187 (179–194) | 0.08 (0.08–0.08) | 11.0 | 14.4 |
| AVP | 8.6 (8.2–9.0) | 155 (151–156) | 0.15 (0.12–0.18) | 13.1 | 14.4 |
| AVP for 8 weeks; first vaccine dose at 3 months | 18.2 (18.1–18.3) | 171 (167–176) | 0.38 (0.34–0.4) | 0.1 | 14.4 |
| AVP | 2.1 (2.0–2.2) | 141 (127–166) | 0.02 (0.02–0.03) | 10.7 | 14.4 |
| AVP | 5.3 (5.2–5.4) | 192 (188–194) | 0.05 (0.05–0.05) | 8.0 | 8.5 |
| AVP | 2.3 (2.2–2.3) | 186 (184–188) | 0.02 (0.02–0.02) | 3.6 | 24.6 |
| AVP | 5.1 (5.0–5.1) | 165 (161–170) | 0.05 (0.05–0.06) | 7.8 | 14.4 |
|
| |||||
| AVP | 4.4 (4.4–4.5) | 274 (253–280) | 0.04 (0.04–0.04) | 6.7 | 14.4 |
| AVP | 4.4 (4.3–4.5) | 251 (246–257) | 0.04 (0.04–0.04) | 6.7 | 14.4 |
| AVP | 4.6 (4.5–4.6) | 222 (210–230) | 0.04 (0.04–0.04) | 7.0 | 14.4 |
|
| |||||
| AVP | 4.6 (4.6–4.8) | 163 (162–165) | 0.04 (0.04–0.04) | 7.2 | 14.4 |
| AVP | 6.2 (6.1–6.3) | 126 (123,129) | 0.12 (0.12–0.13) | 9.5 | 14.4 |
| AVP | 11.0 (10.8–11.1) | 152 (151–156) | 0.28 (0.27–0.28) | 10.2 | 14.4 |
Moderate scenario (R0 = 1.7). VE = 70%; vaccination target categories: personnel providing essential services, elderly persons, indidividuals 2–18 years of age, unless otherwise specified.
AVP = antiviral prophylaxis;
Different vaccine effectiveness for different categories: 59% in individuals 2–18 years of age [16], 70% in individuals 40–64 years of age [15], and 40% in ≥65 year-olds [17];
Unlimited, household contacts;
Vaccine effectiveness = 50%;
air travel restrictions for 2 months after the first national case
Clinical attack rates and peak day, by combination of control measures.
| Control measure | Cumulative AR [%] (95% CI) | Peak day (95% CI) | Peak daily AR [%] (95% CI) | Millions of AVP courses used | Millions of vaccine courses used |
|
| |||||
| AVP | 14.4 (14.4–14.5) | 132 (130–134) | 0.28 (0.28–0.29) | 21.3 | 14.4 |
| AVP | 20.5 (20.1–20.8) | 124 (122–125) | 0.79 (0.77–0.80) | 29.1 | 14.4 |
| AVP | 24.6 (24.5–24.7) | 124 (122–125) | 0.79 (0.77–0.80) | 34.9 | 14.4 |
| AVP | 16.2 (16.1–16.3) | 130 (129–131) | 0.34 (0.33–0.34) | 23.7 | 14.4 |
| AVP | 21.1 (21.0–21.3) | 124 (123–127) | 0.78 (0.77–0.80) | 30.0 | 14.4 |
| AVP | 24.7 (24.6–24.7) | 124 (122–126) | 0.78 (0.77–0.80) | 35.0 | 14.4 |
| AVP | 17.6 (17.4–17.7) | 130 (127–132) | 0.40 (0.39–0.40) | 25.8 | 14.4 |
| AVP | 21.6 (21.3–22.0) | 124 (122–125) | 0.79 (0.77–0.80) | 30.8 | 14.4 |
| AVP | 24.7 (24.6–24.8) | 124 (122–125) | 0.79 (0.77–0.80) | 35.0 | 14.4 |
| AVP for 8 weeks; first vaccine dose at 2 months | 27.4 (27.3–27.4) | 126 (123–130) | 0.98 (0.97–0.99) | 1.5 | 14.4 |
| AVP | 7.9 (7.7–8.1) | 117 (101–127) | 0.14 (0.13–0.15) | 31.8 | 14.4 |
| AVP | 16.0 (16.0–16.1) | 131 (129–134) | 0.32 (0.31–0.33) | 23.2 | 8.5 |
| AVP | 9.0 (8.8–9.3) | 126 (119–132) | 0.16 (0.15–0.17) | 13.6 | 24.6 |
| AVP | 14.7 (14.6,14.8) | 125 (121–128) | 0.29 (0.28–0.3) | 21.8 | 14.4 |
|
| |||||
| AVP | 14.2 (14.1–14.3) | 156 (152–158) | 0.27 (0.26–0.28) | 21.0 | 14.4 |
| AVP | 15.8 (15.5–16.3) | 129 (127,131) | 0.39 (0.35–0.47) | 22.9 | 14.4 |
| AVP | 23.3 (23.0–23.6) | 139 (137–141) | 0.77 (0.75–0.79) | 33.0 | 14.4 |
|
| |||||
| AVP | 16.5 (16.1–16.7) | 99 (97–101) | 0.49 (0.43–0.52) | 24.0 | 14.4 |
| AVP | 23.7 (23.4–23.8) | 109 (107–111) | 0.75 (0.75–0.76) | 33.6 | 14.4 |
| AVP | 24.8 (24.7–24.9) | 109 (107–111) | 0.75 (0.75–0.76) | 35.3 | 14.4 |
Severe scenario (R0 = 2). VE = 70%; vaccination target categories: personnel providing essential services, elderly persons, individuals 2–18 years of age, unless otherwise specified.
AVP = antiviral prophylaxis;
Different vaccine effectiveness for different categories: 59% in individuals 2–18 years of age [16], 70% in individuals 40–64 years of age [15], and 40% in ≥65 year-olds [17];
Unlimited, household contacts;
Vaccine effectiveness = 50%;
air travel restrictions for 2 months after the first national case
Figure 4Cumulative clinical AR, by age and scenario (Panel A: R0 = 1.7; Panel B: R0 = 2).
Black line represents baseline results; red line represents the standard vaccination strategy (i.e., personnel providing essential services; elderly persons; and 2–18 year-olds); green line represents the effect of limiting vaccination to essential workers and children.